Free Trial
→ My prediction for December 8th (From Behind the Markets) (Ad)tc pixel
NASDAQ:CDXS

Codexis Q3 2026 Earnings Date & Estimates

Codexis logo
$1.02 -0.09 (-7.66%)
As of 01:58 PM Eastern

Codexis is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Codexis in Q3 2026

Codexis is expected to post earnings of -$0.0957 per share on revenue of $18.72 million. In the same quarter a year earlier Codexis reported -$0.22 per share on revenue of $8.60 million. Codexis last reported on August 11, 2026, posting -$0.13 per share and beating the -$0.1417 consensus estimate. Codexis has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.0957
Expected Revenue
$18.72 million
Prior-Year EPS
-$0.22
Prior-Year Revenue
$8.60 million
Expected Revenue Growth
+117.6%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.13 (Beat by +$0.0117)
Last Quarter Revenue
$14.92 million
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Codexis Q3 2026 Earnings FAQ

Codexis (NASDAQ:CDXS) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Codexis' Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Codexis to post earnings of -$0.0957 per share for Q3 2026.

The consensus revenue estimate for Codexis is $18.72 million for Q3 2026.

Codexis Earnings Headlines

Codexis Presents Data Validating ECO Synthesis For SiRNA Production; Secures $60 Mln Loan Facility
 |  rttnews.comhttps://www.rttnews.com/3712656/codexis-presents-data-validating-eco-synthesis-for-sirna-production-secures-60-mln-loan-facility.aspx
Codexis Secures New Financing and Repays Prior Loan
November 10 at 8:11 AM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/codexis-secures-new-financing-and-repays-prior-loan?utm_source=marketbeat.com&utm_medium=referral
Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
November 10 at 1:00 AM  |  Behind the Markets (Ad)
Codexis Enters into $60 Million Term Loan Facility with Trinity Capital
November 10 at 6:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/10/3399265/24825/en/codexis-enters-into-60-million-term-loan-facility-with-trinity-capital.html
Contrasting Codexis (NASDAQ:CDXS) & Illumina (NASDAQ:ILMN)
November 10 at 3:59 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31190056
Codexis Advances ECO Synthesis Toward Adoption Readiness with Quality at Scale and Expanded siRNA Manufacturing Capabilities
November 9 at 6:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/09/3398159/24825/en/codexis-advances-eco-synthesis-toward-adoption-readiness-with-quality-at-scale-and-expanded-sirna-manufacturing-capabilities.html
See More Codexis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Codexis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Codexis and other key companies, straight to your email.

About Codexis

Codexis (NASDAQ:CDXS) is a biotechnology company that develops enzymes and other biocatalytic technologies for use in pharmaceutical and biomanufacturing applications. Its proprietary CodeEvolver protein-engineering platform is designed to improve the performance of naturally occurring enzymes, including their activity, selectivity, stability and production characteristics.

The company works with pharmaceutical and biotechnology companies to develop biocatalysts used in the manufacture of active pharmaceutical ingredients, intermediates and other complex molecules. Codexis also offers enzyme products and related development services intended to support more efficient, selective and potentially lower-impact manufacturing processes, including applications involving small-molecule drugs and emerging therapeutic modalities.

Founded in 2002 and headquartered in Redwood City, California, Codexis serves customers internationally through collaborations, licensing arrangements, research and development programs, and commercial enzyme offerings. The company is led by Stephen D. Dilly, who became president and chief executive officer in 2023.

View Codexis Profile
Earnings Tools